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Sphingolipid metabolism potential 
in fecal microbiome and bronchiolitis in infants: 
a case–control study
Kohei Hasegawa1* , Christopher J. Stewart2, Jonathan M. Mansbach3, Rachel W. Linnemann4, Nadim J. Ajami2, 
Joseph F. Petrosino2 and Carlos A. Camargo1
Abstract 
Objective: Emerging evidence demonstrated that the structure of fecal microbiome is associated with the likeli-
hood of bronchiolitis in infants. However, no study has examined functional profiles of fecal microbiome in infants 
with bronchiolitis. In this context, we conducted a case–control study. As a part of multicenter prospective study, we 
collected stool samples from 40 infants hospitalized with bronchiolitis (cases). We concurrently enrolled 115 age-
matched healthy controls.
Results: First, by applying 16S rRNA gene sequencing to these 155 fecal samples, we identified the taxonomic pro-
files of fecal microbiome. Next, based on the taxonomy data, we inferred the functional capabilities of fecal micro-
biome and tested for differences in the functional capabilities between cases and controls. Overall, the median age 
was 3 months and 45% were female. Among 274 metabolic pathways surveyed, there were significant differences 
between bronchiolitis cases and healthy controls for 37 pathways, including lipid metabolic pathways (false discovery 
rate [FDR] <0.05). Particularly, the fecal microbiome of bronchiolitis cases had consistently higher abundances of gene 
function related to the sphingolipid metabolic pathways compared to that of controls (FDR <0.05). These pathways 
were more abundant in infants with Bacteroides-dominant microbiome profile compared to the others (FDR <0.001). 
On the basis of the predicted metagenome in this case–control study, we found significant differences in the func-
tional potential of fecal microbiome between infants with bronchiolitis and healthy controls. Although causal infer-
ences remain premature, our data suggest a potential link between the bacteria-derived metabolites, modulations of 
host immune response, and development of bronchiolitis.
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Introduction
Bronchiolitis is a common acute respiratory infection 
and the leading cause of hospitalizations in US infants 
[1, 2]. Although bronchiolitis has been considered virus-
induced inflammation of small airways [3], recent stud-
ies demonstrate that the pathobiology involves complex 
interrelations among respiratory viruses, host immune 
response, and human microbiome [4–10]. Emerging 
evidence also indicates the existence of “gut-lung axis” 
in which the gut microbiome conditions immunologic 
responses in the lungs to environmental challenges (e.g., 
viral infection) [11]. Indeed, we have previously demon-
strated, in a case–control study of infants hospitalized 
for bronchiolitis and healthy controls [11], that the tax-
onomy profiles of the fecal microbiome were associated 
with the likelihood of bronchiolitis—e.g., infants with the 
Bacteroides-dominant profile were more likely to have 
bronchiolitis. Although previous studies suggest that the 
gut microbiome-derived metabolites (e.g., sphingolipids) 
may play an important role in the host immune develop-
ment [12, 13], the functional profiles of fecal microbiome 
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in infants were not examined in the earlier study. To 
address this knowledge gap, we determined the predicted 
function of fecal microbiome in infants with bronchiolitis 
and healthy infants.
Main text
Methods
This study was a secondary analysis of the data from a 
case–control study of infants hospitalized for bronchi-
olitis and healthy controls. The study design, setting, 
participants, and methods of data collection have been 
reported previously [11]. In brief, as a part of a multi-
center prospective cohort study, called the 35th Multi-
center Airway Research Collaboration (MARC-35) [4–7, 
9], we enrolled 40 infants (aged <12 months) hospitalized 
for an attending physician diagnosis of bronchiolitis from 
November 2013 through April 2014. Bronchiolitis was 
diagnosed according to the American Academy of Pedi-
atrics guidelines [14]. Exclusion criteria were a transfer 
to a participating hospital >48 h after the original hospi-
talization, delayed consent (>24  h after hospitalization), 
gestational age  ≤32  weeks, and known comorbidities 
(cardiopulmonary disease, immunodeficiency, immu-
nosuppression). In addition, during the same period, we 
also enrolled 115 healthy infants as the controls (age-
matched within 1.5  months of cases) [11, 15–17]. We 
excluded infants with current fever, respiratory illness, 
or gastrointestinal illness, antibiotic treatment in the 
preceding 7  days, gestational age ≤32  weeks, or known 
comorbidities. Taken together, a total of 155 infants were 
eligible for the current analysis. From these infants, by 
using a standardized protocol [11, 15, 17], investigators 
conducted a structured interview and medical record 
review, and collected fecal specimens at the time of 
hospitalization (cases) or at home before the clinic visit 
(controls). The fecal samples were immediately stored at 
−80 °C. The institutional review board at each of the par-
ticipating hospitals approved the study. Written informed 
consent was obtained from the parent or guardian.
16S rRNA gene sequencing was performed based 
on the methods adapted from the NIH Human Micro-
biome Project. Briefly, bacterial genomic DNA was 
extracted using MO BIO PowerMag DNA Isolation Kit 
(Mo Bio Lab; Carlsbad, CA). The 16S rDNA V4 regions 
were amplified by PCR and sequenced in the MiSeq 
platform (Illumina; SanDiego, CA) using 2  ×  250  bp 
paired-end protocol. Sequencing read pairs were demul-
tiplexed based on the unique molecular barcodes, and 
reads were merged using USEARCH v7.0.1090, allow-
ing no mismatches and a minimum overlap of 50 bases. 
We trimmed the merged reads at the first base with a 
Q5 quality score. We calculated the expected error after 
taking into account all Q scores across all the bases of a 
read and the probability of an error occurring. We also 
applied a quality filter to the resulting merged reads, dis-
carded the reads containing  >0.05 expected errors. We 
constructed rarefaction curves of bacterial operational 
taxonomic units (OTUs) using sequence data for each 
sample to ensure coverage of the bacterial diversity pre-
sent (Fig.  1). 16S rRNA gene sequences were clustered 
into OTUs at a similarity cutoff value of 97% using the 
UPARSE algorithm; OTUs were mapped to the SILVA 
Database to determine taxonomies. Abundances were 
recovered by mapping the demultiplexed reads to the 
UPARSE OTUs.
To infer the functional capabilities of the fecal micro-
biome based on the OTU (taxonomy) data, we used a 
bioinformatic approach, Tax4Fun [18]. This approach 
links the 16S rRNA gene sequences with the functional 
annotation of sequenced bacterial genomes by identify-
ing a nearest neighbor based on a minimal 16S rRNA 
gene sequence similarity. Next, the predicted metage-
nomes were categorized by function at the Kyoto Ency-
clopedia of Genes and Genomes (KEGG) ortholog and 
pathway levels [19]. We tested for significant differences 
in the functional category abundances between cases and 
controls using Welch’s unequal variances t test. Result-
ing P values were adjusted for multiple hypothesis testing 
by converting to false discovery rate q values using the 
Benjamini–Hochberg procedure, with q values of  <0.05 
considered statistically significant. To validate the find-
ings, we performed random permutation testing with 
1000 permutations for each of the pathways of interest, 
which corresponds to the situation when the abundance 
of pathways is randomly assigned to cases and controls 
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Fig. 1 Rarefaction curves for bacterial operational taxonomic units of 
the fecal microbiome. The horizontal axis indicates sequence depth 
while the vertical axis indicates the number of bacterial operational 
taxonomic units (OTUs). All 155 fecal specimens had sufficient depth 
to obtain high degree of sequence coverage (rarefaction cutoff, 1470 
reads/specimen)
Page 3 of 12Hasegawa et al. BMC Res Notes  (2017) 10:325 
contained in dataset. Once the dataset was permuted, we 
tested for the differences in abundances between cases 
and controls. We repeated the randomization 1000 times 
and recorded the squared error of the models averaged 
for every repetition. Additionally, to further examine the 
differences in the pathways of interest, we constructed 
multivariable linear regression models adjusting for 
potential confounders (age, sex, race/ethnicity, maternal 
antibiotic use during pregnancy, history of prematurity, 
mode of delivery, feeding status, and lifetime history 
of antibiotic and corticosteroid use), based on a priori 
knowledge [5, 6, 9]. Furthermore, to determine the rela-
tionship between the abundance of bacteria genus and 
metabolic pathways of interest, we examined their corre-
lations with the use of scatterplots fitting locally weighted 
scatterplot smoothed (LOWESS) curve as well as Spear-
man’s correlation. The analyses used R version 3.3 with 
phyloseq package [20] and STAMP version 2.1 [21].
Results
At the four participating hospitals, a total of 40 infants 
hospitalized for bronchiolitis (cases) and 115 age-
matched healthy infants (controls) were enrolled 
(Table  1). Overall, the median age was 3  months (IQR, 
2–5 months) and 55% were male. All 155 fecal specimens 
had sufficient depth to obtain high degree of sequence 
Table 1 Patient characteristics of 40 cases (infants with bronchiolitis) and 115 controls (healthy infants) at enrollment
Data are no. (%) of infants unless otherwise indicated. Percentages may not equal 100 because of missingness or rounding
IQR interquartile range
* Chi square, Fisher exact, or Wilcoxon-Mann–Whitney tests, as appropriate
a Defined as an infant having cough that wakes him/her at night and/or causes emesis, or when the child has wheezing or shortness of breath without cough
b Lifetime use of systemic antibiotic use before the enrollment. Infants with systemic antibiotic treatment in the preceding 7 days were not enrolled to the control 
group
Characteristics Infants with bronchiolitis n = 40 Healthy control infants n = 115 P value* 
Demographics
 Age (mo), median (IQR) 3.2 (1.6–4.9) 3.8 (2.0–4.9) 0.52
 Male sex 22 (55) 64 (56) 0.99
  Race/ethnicity 0.04
  Non-hispanic white 23 (58) 61 (53)
  Non-hispanic black 6 (15) 11 (10)
  Hispanic 10 (25) 19 (17)
  Other 1 (3) 24 (21)
Prenatal history
 Parental history of asthma 16 (40) 21 (18) 0.01
 Maternal smoking during pregnancy 8 (20) 3 (3) 0.001
 Maternal antibiotic use during pregnancy 11 (28) 13 (11) 0.02
 Maternal antibiotic use during labor 12 (30) 35 (30) 0.82
Past medical history and home environmental characteristics
 Mode of birth, C-section 9 (23) 43 (37) 0.13
 Prematurity (32–37 weeks) 12 (30) 11 (10) 0.004
 Previous breathing problems before enrollment† 8 (20) 0 (0) <0.001
 History of eczema 8 (20) 17 (15) 0.56
 Ever attended daycare 9 (23) 14 (12) 0.16
 Smoking exposure at home 8 (20) 4 (3) 0.002
 Mostly breastfed for the first 3 months of age 16 (40) 89 (77) 0.009
 Systemic antibiotic use before  enrollmentb 8 (20) 13 (11) 0.24
 Systemic corticosteroid use before enrollment 9 (23) 0 (0) <0.001
Clinical course
 Systemic antibiotic use during pre-hospitalization visit 8 (20) – –
 Systemic corticosteroid use during pre-hospitalization visit 3 (8) – –
 Hospital length-of-stay (day), median (IQR) 3 (2–4) – –
 Admission to intensive care unit 8 (20) – –
 Use of mechanical  ventilationa 5 (13) – –
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coverage (rarefaction cutoff, 1470 reads/specimen; 
Fig.  1). The fecal microbiome were dominated by four 
genera: Escherichia (22%), Bifidobacterium (19%), Entero-
bacter (15%), and Bacteroides (13%). The characteristics 
of the fecal microbiome differed between cases and con-
trols (Table  2). For example, infants with bronchiolitis 
had a higher proportion of Bacteroides-dominant profile 
and lower proportion of Enterobacter/Veillonella-domi-
nant profile, compared to healthy controls (P = 0.01).
Between the infants with bronchiolitis and healthy 
controls, we compared the functional potential of fecal 
microbiome inferred from the 16S rRNA gene sequenc-
ing data. Of 6402 KEGG orthologs (orthologous genes) 
surveyed, the abundances of 319 genes were significantly 
different (q  <  0.05; Table  3). The functional differences 
involved genes with diverse metabolic functions—e.g., 
carbohydrate, amino acid, and lipid metabolism. To make 
the data presentation and interpretation more meaning-
ful, the genes were further consolidated into 274 KEGG 
pathways. Among these, there were significant differ-
ences between bronchiolitis cases and healthy controls 
for 37 pathways, including lipid metabolic pathways 
(q  <  0.05; Table  4; Fig.  2). Particularly, the fecal micro-
biome of bronchiolitis cases had consistently higher 
abundances of gene function related to the sphingolipid 
metabolic pathways compared to that of controls (all 
q  <  0.05)—i.e., sphingolipid (ko00600) and glycosphin-
golipid (ko00603, ko00604) metabolic pathways (Fig.  3). 
For each of these 3 pathways, the permutation test was 
significant (all random permutation P < 0.05), supporting 
the validity of the observed between-group differences. 
In the multivariable models adjusting for 9 patient-level 
factors (age, sex, race/ethnicity, maternal antibiotic use 
during pregnancy, history of prematurity, mode of deliv-
ery, feeding status, and lifetime history of antibiotic and 
corticosteroid use), the difference in the abundances of 
3 sphingolipid metabolic pathways remained significant 
(all P  <  0.05). Additionally, these pathways were more 
abundant in infants with Bacteroides-dominant micro-
biome profile compared to the other microbiome pro-
files (all q < 0.001; Fig. 4). Likewise, there was a positive 
correlation between the abundance of Bacteroides genus 
and each of the 3 sphingolipid metabolic pathways (all 
P < 0.001; Fig. 5; Table 4).
Discussion
By predicting the functional potential of the fecal micro-
biome from 40 infants with bronchiolitis and 115 healthy 
age-matched controls enrolled in a case–control study, 
we found significant differences in the abundance of 
genes related to multiple metabolic pathways. Of these, 
the gene function related to sphingolipid metabolic 
Table 2 Richness, alpha-diversity, and relative abundance of fecal microbiome in infants with bronchiolitis and healthy 
controls
IQR interquartile range
* Benjamini–Hochberg corrected false discovery rate (q value) accounting for multiple comparisons
Infants with bronchiolitis n = 40 Healthy control infants n = 115 P value
Richness, median (IQR)
 Number of genera 17 (13–23) 13 (10–18) 0.004
Alpha-diversity, median (IQR) shannon index 2.21 (1.68–2.65) 1.93 (1.44–2.49) 0.27
Relative abundance of 10 most abundant genera, mean (standard deviation)
 Escherichia 0.21 (0.24) 0.23 (0.26) 0.91*
 Bifidobacterium 0.16 (0.20) 0.20 (0.21) 0.49*
 Enterobacter 0.10 (0.21) 0.17 (0.24) 0.27*
 Bacteroides 0.20 (0.23) 0.10 (0.19) 0.10*
 Veillonella 0.03 (0.09) 0.06 (0.12) 0.31*
 Lachnospiraceae incertae sedis 0.06 (0.10) 0.04 (0.10) 0.49*
 Streptococcus 0.02 (0.09) 0.03 (0.05) 0.91*
 Clostridium sensu strictos 1 0.01 (0.01) 0.03 (0.06) 0.16*
 Enterococcus 0.01 (0.03) 0.02 (0.04) 0.48*
 Akkermansia 0.02 (0.09) 0.02 (0.08) 0.91*
Microbiome profile, n (%) 0.01
 Bacteroides-dominant profile 19 (48) 24 (21)
 Bifidobacterium-dominant profile 6 (15) 26 (23)
 Escherichia-dominant profile 10 (25) 36 (31)
 Enterobacter/Veillonella-dominant profile 5 (12) 29 (25)
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Table 3 Predicted KEGG orthologs with significant differences in relative abundance between infants with bronchiolitis 
and healthy controls
KEGG orthologs Mean abundance 
in cases (%)
Mean abundance 
in controls (%)
Raw P 
value
FDR corrected 
q value
K00179; indolepyruvate ferredoxin oxidoreductase, alpha subunit [EC:1.2.7.8] 0.020 0.009 <0.001 0.026
K00180; indolepyruvate ferredoxin oxidoreductase, beta subunit [EC:1.2.7.8] 0.007 0.003 <0.001 0.028
K02489; two-component system, cell cycle sensor kinase and response regula-
tor [EC:2.7.13.3]
0.004 0.002 0.001 0.038
K03319; divalent anion:Na+ symporter, DASS family 0.019 0.044 <0.001 0.028
K08082; two-component system, LytT family, sensor histidine kinase AlgZ 
[EC:2.7.13.3]
0.011 0.005 0.001 0.041
K08196; MFS transporter, AAHS family, cis, cis-muconate transporter 0.001 0.002 0.002 0.044
K10715; two-component system, sensor histidine kinase RpfC [EC:2.7.13.3] 0.009 0.005 0.001 0.036
K10916; two-component system, CAI-1 autoinducer sensor kinase/phos-
phatase CqsS [EC:2.7.13.3 3.1.3.-]
0.001 0.000 0.001 0.031
K11382; MFS transporter, OPA family, phosphoglycerate transporter protein 0.006 0.015 0.000 0.028
K11383; two-component system, NtrC family, sensor histidine kinase KinB 
[EC:2.7.13.3]
0.001 0.000 0.001 0.034
K11520; two-component system, OmpR family, manganese sensing sensor 
histidine kinase [EC:2.7.13.3]
0.001 0.000 0.000 0.028
K11527; two-component system, unclassified family, sensor histidine kinase 
and response regulator [EC:2.7.13.3]
0.023 0.011 0.001 0.038
K15850; two-component system, autoinducer 1 sensor kinase/phosphatase 
LuxN [EC:2.7.13.3 3.1.3.-]
0.001 0.000 <0.001 0.026
K15913; UDP-4-amino-4,6-dideoxy-N-acetyl-d-glucosamine 4-acetyltransferase 
[EC:2.3.1.-]
0.000 0.000 0.002 0.049
K16014; ATP-binding cassette, subfamily C, bacterial CydCD 0.005 0.010 0.002 0.042
K00176; 2-oxoglutarate ferredoxin oxidoreductase subunit delta [EC:1.2.7.3] 0.001 0.001 0.001 0.035
K00177; 2-oxoglutarate ferredoxin oxidoreductase subunit gamma [EC:1.2.7.3] 0.010 0.005 0.001 0.041
K00200; formylmethanofuran dehydrogenase subunit A [EC:1.2.99.5] 0.001 0.000 0.001 0.038
K00316; spermidine dehydrogenase [EC:1.5.99.6] 0.000 0.000 0.002 0.046
K00406; cytochrome c oxidase cbb3-type subunit III 0.002 0.004 0.001 0.030
K00436; hydrogen dehydrogenase [EC:1.12.1.2] 0.002 0.001 <0.001 0.023
K00824; d-alanine transaminase [EC:2.6.1.21] 0.004 0.008 0.002 0.045
K00832; aromatic-amino-acid transaminase [EC:2.6.1.57] 0.010 0.020 <0.001 0.026
K00856; adenosine kinase [EC:2.7.1.20] 0.002 0.001 0.001 0.034
K00908; Ca2+/calmodulin-dependent protein kinase [EC:2.7.11.17] 0.001 0.000 <0.001 0.023
K01235; alpha-glucuronidase [EC:3.2.1.139] 0.017 0.008 0.002 0.041
K01601; ribulose-bisphosphate carboxylase large chain [EC:4.1.1.39] 0.003 0.010 0.002 0.042
K01841; phosphoenolpyruvate phosphomutase [EC:5.4.2.9] 0.008 0.004 0.002 0.049
K01906; 6-carboxyhexanoate–CoA ligase [EC:6.2.1.14] 0.003 0.007 0.001 0.037
K01912; phenylacetate-CoA ligase [EC:6.2.1.30] 0.037 0.018 0.001 0.041
K02121; V-type H+ -transporting ATPase subunit E [EC:3.6.3.14] 0.010 0.005 <0.001 0.024
K02655; type IV pilus assembly protein PilE 0.002 0.005 <0.001 0.023
K03330; glutamyl-tRNA (Gln) amidotransferase subunit E [EC:6.3.5.7] 0.001 0.003 0.001 0.042
K03404; magnesium chelatase subunit D [EC:6.6.1.1] 0.007 0.019 0.002 0.046
K03756; putrescine:ornithine antiporter 0.007 0.016 <0.001 0.024
K04561; nitric oxide reductase subunit B [EC:1.7.2.5] 0.006 0.017 <0.001 0.026
K05586; bidirectional [NiFe] hydrogenase diaphorase subunit [EC:1.6.5.3] 0.001 0.000 0.001 0.032
K05588; bidirectional [NiFe] hydrogenase diaphorase subunit [EC:1.6.5.3] 0.001 0.000 0.002 0.043
K05589; cell division protein FtsB 0.002 0.003 <0.001 0.024
K05989; alpha-l-rhamnosidase [EC:3.2.1.40] 0.056 0.028 0.002 0.045
K06138; pyrroloquinoline quinone biosynthesis protein D 0.001 0.000 0.001 0.034
K07326; hemolysin activation/secretion protein 0.001 0.003 <0.001 0.026
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pathways was consistently more abundant in the fecal 
microbiome of bronchiolitis cases compared to that of 
healthy controls. The current study extends the previ-
ously identified association of Bacteroides-dominated 
fecal microbiome profile with higher likelihoods of bron-
chiolitis by demonstrating the functional potential of the 
gut microbiome in infants.
Sphingolipids are a class of complex lipids contain-
ing a backbone of sphingoid bases. These lipids have 
long been known as structural components of human 
cell membranes and as a component of surfactant, but 
have more recently emerged as signaling molecules that 
modulate the host immune response and contribute to 
the pathogenesis of respiratory diseases, such as bron-
chiolitis, pneumonia, and asthma [7, 22]. While sphin-
golipids production is ubiquitous in eukaryotes, it is also 
produced by several bacteria genera such as Bacteroides, 
Prevotella, and Porphyromonas [12]. Recently, experi-
mental models reported that Bacteroides-derived sphin-
golipids (e.g., α-galactosylceramide) play an important 
role in host immunomodulation similar to lipopolysac-
charide (LPS), another family of bacteria-derived gly-
colipid. For example, Wieland Brown et al. demonstrated 
that Bacteroides-derived α-galactosylceramide binds to 
Table 3 continued
KEGG orthologs Mean abundance 
in cases (%)
Mean abundance 
in controls (%)
Raw P 
value
FDR corrected 
q value
K07536; 2-ketocyclohexanecarboxyl-CoA hydrolase [EC:3.1.2.-] 0.001 0.002 0.001 0.041
K09002; hypothetical protein 0.006 0.018 0.001 0.041
K09020; ureidoacrylate peracid hydrolase [EC:3.5.1.110] 0.002 0.003 0.001 0.031
K09162; hypothetical protein 0.003 0.008 0.001 0.034
K09459; phosphonopyruvate decarboxylase [EC:4.1.1.82] 0.005 0.003 0.003 0.050
K09477; citrate:succinate antiporter 0.008 0.016 0.001 0.034
K09758; aspartate 4-decarboxylase [EC:4.1.1.12] 0.015 0.007 <0.001 0.026
K09800; hypothetical protein 0.025 0.053 <0.001 0.026
K09824; hypothetical protein 0.007 0.014 <0.001 0.026
K10960; geranylgeranyl reductase [EC:1.3.1.83] 0.001 0.000 <0.001 0.027
K10974; cytosine permease 0.007 0.016 <0.001 0.026
K11016; hemolysin 0.001 0.002 0.001 0.029
K11106; l-tartrate/succinate antiporter 0.009 0.020 <0.001 0.026
K11607; manganese/iron transport system ATP-binding protein 0.004 0.009 <0.001 0.022
K11707; manganese/zinc/iron transport system substrate-binding protein 0.003 0.007 0.001 0.041
K11708; manganese/zinc/iron transport system permease protein 0.003 0.007 0.002 0.042
K11709; manganese/zinc/iron transport system permease protein 0.004 0.008 0.001 0.034
K11719; lipopolysaccharide export system protein LptC 0.003 0.007 <0.001 0.023
K11931; biofilm PGA synthesis lipoprotein PgaB [EC:3.-.-.-] 0.008 0.016 <0.001 0.028
K12341; adhesin YadA 0.005 0.012 0.001 0.041
K12681; pertactin 0.001 0.002 0.002 0.041
K12982; heptosyltransferase I [EC:2.4.-.-] 0.001 0.002 <0.001 0.028
K13256; protein PsiE 0.003 0.006 <0.001 0.029
K13498; indole-3-glycerol phosphate synthase/phosphoribosylanthranilate 
isomerase [EC:4.1.1.48 5.3.1.24]
0.008 0.017 <0.001 0.022
K13818; molybdopterin-guanine dinucleotide biosynthesis protein 0.001 0.003 0.001 0.029
K14448; (2S)-methylsuccinyl-CoA dehydrogenase 0.002 0.001 0.001 0.032
K14564; nucleolar protein 56 0.001 0.000 0.002 0.043
K14665; amidohydrolase [EC:3.5.1.-] 0.002 0.004 0.001 0.031
K15125; filamentous hemagglutinin 0.032 0.092 0.000 0.024
K15669; d-glycero-alpha-d-manno-heptose 1-phosphate guanylyltransferase 
[EC:2.7.7.71]
0.002 0.001 0.001 0.031
K15905; nitrite oxidoreductase alpha subunit 0.001 0.003 0.001 0.041
K16201; dipeptide transport system permease protein 0.001 0.003 0.002 0.045
Of 6402 KEGG orthologs surveyed, the relative abundances of 319 genes were significantly different (FDR, q < 0.05) between infants with bronchiolitis and healthy 
controls. Of these, 74 orthologs with a ratio of abundance >2.0 are displayed
Page 7 of 12Hasegawa et al. BMC Res Notes  (2017) 10:325 
Table 4 Predicted KEGG pathways with significant differences in relative abundance between infants with bronchiolitis 
and healthy controls
Italics results are the pathways of interest (sphingolipid metabolic pathways)
KEGG pathway Difference in relative abundance Correlation with  
Bacteroides abundance
Mean  
abundance 
in cases (%)
Mean  
abundance 
in controls (%)
Raw  
P value
FDR corrected  
q value
Spearman’s  
rho
P value
ko00051; fructose and mannose metabolism 1.691 1.447 0.001 0.043 0.55 <0.001
ko00052; galactose metabolism 1.473 1.298 0.004 0.035 0.66 <0.001
ko00140; steroid hormone biosynthesis 0.098 0.063 0.007 0.049 0.66 <0.001
ko00190; oxidative phosphorylation 1.332 1.215 0.005 0.041 0.41 <0.001
ko00311; penicillin and cephalosporin biosynthesis 0.068 0.060 0.001 0.041 0.44 <0.001
ko00450; selenocompound metabolism 0.626 0.703 0.001 0.046 −0.61 <0.001
ko00460; cyanoamino acid metabolism 0.280 0.222 0.004 0.037 0.82 <0.001
ko00472; d-arginine and d-ornithine metabolism 0.001 0.002 0.004 0.037 −0.52 <0.001
ko00480; glutathione metabolism 0.678 0.764 0.001 0.035 −0.49 <0.001
ko00511; other glycan degradation 1.198 0.910 0.002 0.035 0.72 <0.001
ko00520; amino sugar and nucleotide sugar 
metabolism
2.751 2.450 0.002 0.037 0.77 <0.001
ko00523; polyketide sugar unit biosynthesis 0.196 0.163 0.002 0.035 0.80 <0.001
ko00531; glycosaminoglycan degradation 0.256 0.152 0.005 0.044 0.73 <0.001
ko00532; glycosaminoglycan biosynthesis 0.035 0.026 0.001 0.048 0.72 <0.001
ko00591; linoleic acid metabolism 0.120 0.113 0.006 0.047 0.52 <0.001
ko00600; sphingolipid metabolism 0.489 0.351 0.003 0.034 0.77 <0.001
ko00603; glycosphingolipid biosynthesis 0.134 0.097 0.003 0.031 0.73 <0.001
ko00604; glycosphingolipid biosynthesis 0.061 0.039 0.006 0.048 0.74 <0.001
ko00642; Ethylbenzene degradation 0.084 0.075 0.002 0.034 0.25 0.001
ko00660; C5-branched dibasic acid metabolism 0.171 0.191 <0.001 0.028 −0.50 <0.001
ko00940; phenylpropanoid biosynthesis 0.213 0.163 0.006 0.048 0.81 <0.001
ko00944; flavone and flavonol biosynthesis 0.015 0.009 0.002 0.036 0.77 <0.001
ko03015; mRNA surveillance pathway 0.003 0.001 0.003 0.032 0.80 <0.001
ko04141; protein processing in endoplasmic 
reticulum
0.063 0.049 0.006 0.049 0.69 <0.001
ko04142; lysosome 0.310 0.194 0.006 0.047 0.76 <0.001
ko04210; apoptosis 0.043 0.025 0.002 0.030 0.69 <0.001
ko04612; antigen processing and presentation 0.014 0.010 0.002 0.031 0.58 <0.001
ko04621; NOD-like receptor signaling pathway 0.056 0.042 0.001 0.040 0.74 <0.001
ko04721; synaptic vesicle cycle 0.001 0.000 0.002 0.033 0.58 <0.001
ko04725; cholinergic synapse 0.002 0.005 0.003 0.031 −0.12 0.14
ko04914; progesterone-mediated oocyte matura-
tion
0.014 0.010 0.002 0.033 0.58 <0.001
ko04930; type II diabetes mellitus 0.026 0.028 0.001 0.036 −0.47 <0.001
ko04962; vasopressin-regulated water reabsorption 0.001 0.000 0.002 0.036 0.58 <0.001
ko05110; vibrio cholerae infection 0.001 0.004 0.006 0.046 −0.41 <0.001
ko05133; pertussis 0.356 0.609 0.002 0.029 −0.24 0.03
ko05211; renal cell carcinoma 0.013 0.019 <0.001 0.028 −0.58 <0.001
ko05215; prostate cancer 0.016 0.011 0.002 0.037 0.63 <0.001
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CD1d and activates mouse and human invariant natu-
ral killer T (iNKT) cells both in vitro and in vivo [12]. In 
contrast, An et al., using neonatal mouse models, found 
that treatment with a different Bacteroides-derived gly-
cosphingolipids (GSL-Bf717) reduces the number of 
colonic iNKT cells and subsequent colonic inflammation 
[13]. Although reverse causation—e.g., bronchiolitis per 
se or treatments for bronchiolitis result in perturbation 
of the fecal microbiome—is also possible, these prior 
studies, coupled with our findings, collectively sug-
gest that Bacteroides-dominant microbiome in the gut, 
through their sphingolipid production, may contribute 
to inappropriate immune responses and bronchioli-
tis pathogenesis in infants. Our data should encourage 
future investigations into the mechanisms linking the 
individual gut microbiome-derived metabolites to the 
host immune response in the gut and respiratory tract 
(the gut-lung axis).
Fig. 2 Predicted KEGG pathways with significant differences in relative abundance between infants with bronchiolitis and healthy controls. Of 
274 KEGG pathways surveyed, the relative abundance of 37 genes was significantly different (false discovery rate, q < 0.05) between infants with 
bronchiolitis and healthy controls
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In sum, on the basis of the predicted metagenome 
in this case–control study, we found significant differ-
ences in the functional potential of fecal microbiome 
between infants with bronchiolitis and healthy con-
trols. Particularly, the fecal microbiome in infants with 
bronchiolitis had consistently higher abundances of 
gene function related to the sphingolipid metabolic 
pathways. Although causal inferences remain prema-
ture, our data may suggest a potential link between 
the bacteria-derived metabolites, modulations of host 
immune response, and development of bronchioli-
tis. Our findings should facilitate further metagen-
omic, metatranscriptomic, and metabolomic (including 
Bacteroides-derived galactosylceramide [13]) investiga-
tions into the role of gut microbiome in the bronchioli-
tis pathogenesis. Our data also encourage researchers 
to integrate these “omics” approaches with mechanistic 
evaluations in experimental models in order to develop 
new preventive and therapeutic strategies (e.g., microbi-
ome modification) for infants with bronchiolitis.
Limitations
Our study has several potential limitations. First, the 
location of fecal sample collection differed between cases 
and controls. However, in both populations, the fecal 
samples were refrigerated immediately after collection 
Fig. 3 Box-whisker plots of the three sphingolipid metabolic pathways that distinguish between the fecal microbiome of infants with bronchiolitis 
and that of healthy controls. The predicted metagenome of fecal microbiome in infants with bronchiolitis had a higher abundance of the a ko00600 
(q = 0.03), b ko00603 (q = 0.03), and c ko00604 (q = 0.048) pathways compared to that in healthy controls. The horizontal line represents the 
median; the bottom and the top of the box represent the 25th and the 75th percentiles; whiskers represent 5 and 95% percentiles
Page 10 of 12Hasegawa et al. BMC Res Notes  (2017) 10:325 
and the literature reported that refrigeration is associ-
ated with no significant alteration in fecal microbiota 
composition [23]. Second, the functional potential of 
fecal microbiome was inferred from the 16S rRNA 
gene sequencing data rather than measured by metabo-
lomics or metatranscriptomics, or from metagenomic 
sequencing. However, a study has shown a strong corre-
lation between the predicted metagenome and metage-
nome sequencing data (r  >  0.85) in the NIH Human 
Microbiome Project samples (including fecal samples) 
[18]. Third, the concentration of metabolites was not 
measured in the fecal samples. This is an important area 
Fig. 4 Box-whisker plots of the three sphingolipid metabolic pathways that distinguish four fecal microbiome profiles. The relative abundance of 
a ko00600, b ko00603, and c ko00604 pathways were consistently higher in infants with Bacteroides-dominant microbiome profile compared to 
the others (all q < 0.001). The four fecal microbiota profiles were derived using partitioning around medoids clustering method with Bray–Curtis 
distance. The optimal number of clusters was identified by the use of gap statistic. The horizontal line represents the median; the bottom and the top 
of the box represent the 25th and the 75th percentiles; whiskers represent 5 and 95% percentiles. BCP Bacteroides-dominant profile, BFP Bifidobacte-
rium-dominant profile, ESP Escherichia-dominated profile, EVP Enterobacter/Veillonella-dominant profile
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for examination in our future work. Lastly, the study 
design precluded us from examining the succession of 
fecal microbiome and its relation to the development of 
respiratory disease in early childhood. To address this 
question, the study populations are currently being fol-
lowed longitudinally to age 6 years, with fecal sample col-
lections at multiple time-points.
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